Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Exicure, Inc. - Common Stock (NQ:XCUR)

4.475 +0.035 (+0.78%)
Streaming Delayed Price Updated: 12:21 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Exicure, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
Exicure, Inc. Reports Second Quarter 2025 Financial Results
From Exicure, Inc.
Via Business Wire
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements
From Exicure, Inc.
Via Business Wire
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
From Exicure, Inc.
Via Business Wire
Exicure, Inc. Reports First Quarter 2025 Financial Results
From Exicure, Inc.
Via Business Wire
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
From Exicure, Inc.
Via Business Wire
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
From Exicure, Inc.
Via Business Wire
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma
From Exicure, Inc.
Via Business Wire
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)
From Exicure, Inc.
Via Business Wire
Exicure, Inc. Reports Full Year 2024 Financial Results
From Exicure, Inc.
Via Business Wire
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia
From Exicure, Inc.
Via Business Wire
CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
From Exicure, Inc.
Via Business Wire
Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech
From Exicure, Inc.
Via Business Wire
CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes
From Exicure, Inc.
Via Business Wire
Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results
From Exicure, Inc.
Via Business Wire
Exicure, Inc. Receives Extension from Nasdaq Hearings Panel
From Exicure, Inc.
Via Business Wire
Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation
From Exicure, Inc.
Via Business Wire
Exicure, Inc. Announces 1-for-5 Reverse Stock Split
From Exicure, Inc.
Via Business Wire
Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting
From Exicure, Inc.
Via Business Wire
Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
From Exicure, Inc.
Via Business Wire
Exicure, Inc. Reports Second Quarter 2024 Financial Results
From Exicure, Inc.
Via Business Wire
Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics
From Exicure, Inc.
Via Business Wire
Exicure, Inc. Receives Positive Listing Determination from Nasdaq
From Exicure, Inc.
Via Business Wire
Exicure, Inc. Reports First Quarter 2024 Financial Results
From Exicure, Inc.
Via Business Wire
Exicure, Inc. Reports Full Year 2023 Financial Results
From Exicure, Inc.
Via Business Wire
Exicure, Inc. Received Nasdaq Notice of a Delisting Determination
From Exicure, Inc.
Via Business Wire
Exicure, Inc. Reports Third Quarter 2023 Financial Results
From Exicure, Inc.
Via Business Wire
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
From Exicure, Inc.
Via Business Wire
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
From Exicure, Inc.
Via Business Wire
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
From Exicure, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.